Zcube srl, a venture arm of Italian drug maker Zambon Co. SpA, will licensed UCSF-developed technology so it can find new ways to deliver oral medications directly to a target.It is the first sponsored research agreement between Zcube and the University of California, San Francisco, though Zcube a year ago invested $1 million in Mission Bay Capital, a seed fund established by QB3 director Regis Kelly, venture capital guru Brook Byers and others.
Exact financial terms of the two-year exclusive, worldwide licensing deal were not disclosed. But UCSF could receive milestone payments and royalties.
